Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:17:55 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:NBIX - NEUROCRINE BIOSCIENCES INC - https://WWW.NEUROCRINE.COM
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NBIX - Q0.1124.25·139.570.3132.02-2.09-1.6757.799,49910,862134.94  134.94  131.12157.9799  84.2316:09:42Jul 1515 min RT 2¢

Recent Trades - Last 10 of 10862
Time ETExPriceChangeVolume
16:09:42Q132.02-2.0915
16:04:15Q132.02-2.091
16:04:15Q132.02-2.091
16:04:14Q132.02-2.091
16:04:14Q132.02-2.091
16:04:08Q132.02-2.091
16:04:07Q132.02-2.091
16:04:05Q132.02-2.091
16:04:04Q132.02-2.091
16:01:49Q132.02-2.091,834

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-15 09:00U:NBIXNews ReleaseNeurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
2025-07-15 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents New Analysis of CAHtalog(TM) Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
2025-07-14 16:35U:NBIXNews ReleaseNeurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst(TM) Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
2025-07-14 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY(TM) (crinecerfont) in Adult Patients, at ENDO 2025
2025-07-09 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
2025-06-30 16:05U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
2025-06-27 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT(TM)-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA(TM) (valbenazine) Capsules for Huntington's Disease Chorea
2025-06-20 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA(TM) (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
2025-06-09 16:05U:NBIXNews ReleaseNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
2025-06-02 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO(TM) Study Demonstrating INGREZZA(TM) (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
2025-05-30 16:30U:NBIXNews ReleaseFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
2025-05-28 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
2025-05-16 08:30U:NBIXNews ReleaseNeurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst(TM) Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
2025-05-16 08:25U:NBIXNews ReleaseNeurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
2025-05-15 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY(TM) (crinecerfont)
2025-05-14 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
2025-05-08 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst(TM) Pediatric Study Demonstrating CRENESSITY(TM) Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
2025-05-06 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at Upcoming Investor Conferences in May
2025-05-06 08:30U:NBIXNews ReleaseNeurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie(TM) Awareness Campaign for People with Tardive Dyskinesia
2025-05-05 16:01U:NBIXNews ReleaseNeurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance